Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04OBB
|
|||
| Former ID |
DAP001063
|
|||
| Drug Name |
Pheniramine
|
|||
| Synonyms |
Avil; Feniramina; Feniramine; Histapyridamine; Metron; Pheniraminum; Propheniramine; Prophenpyridamine; Pyriton; Trimeton; Tripoton; Pheniramine Bimaleate; Avil (TN); Feniramina [INN-Spanish]; P-Aminosalicylsaures salz; Pheniramine (INN); Pheniramine [INN:BAN]; Pheniraminum [INN-Latin]; PHENIRAMINE (SEE ALSO PHENIRAMINE MALEATE 132-20-7); Dimethyl(3-phenyl-3-(2-pyridyl)propyl)amine; N,N-Dimethyl-3-phenyl-3-(2-pyridyl)propylamine; N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine; 1-Phenyl-1-(2-pyridyl)-3-dimethylaminopropane; 2-(3-Dimethylamino-1-phenylpropyl)pyridine; 2-(alpha-(2-Dimethylaminoethyl)benzyl)pyridine; 2-Pyridinepropanamine, N,N-dimethyl-gamma-phenyl-(9CI); 2-[.alpha.-(2-Dimethylaminoethyl)benzyl]pyridine; 2-[.alpha.-[2-(Dimethylamino)ethyl]benzyl]pyridine; 3-Phenyl-3-(2-pyridyl)-N,N-dimethylpropylamine; 3-Phenyl-3-(2-pyridyl)-N,N-dimethylpropylanine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hay fever [ICD-11: CA08.00; ICD-10: J30.1; ICD-9: 477] | Approved | [1], [2] | |
| Therapeutic Class |
Antiallergic Agents
|
|||
| Company |
Aventis Pharmaceuticals Inc.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H20N2
|
|||
| Canonical SMILES |
CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2
|
|||
| InChI |
1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3
|
|||
| InChIKey |
IJHNSHDBIRRJRN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 86-21-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
100679, 615214, 4437708, 8152922, 10537059, 11335410, 11360649, 11363969, 11366531, 11369093, 11371700, 11374450, 11377255, 11461621, 11466087, 11467207, 11485010, 11485874, 11489093, 11490576, 11492781, 11494889, 15196427, 25719831, 29223845, 46505932, 47365068, 47365069, 47588879, 47662152, 47959615, 47959616, 48110340, 48184880, 48184881, 48416413, 49698877, 49855960, 50111204, 57322434, 77594960, 85787923, 90341510, 96025042, 103357869, 103928924, 104307349, 124750145, 124881161, 125677793
|
|||
| ChEBI ID |
CHEBI:91591
|
|||
| SuperDrug ATC ID |
R06AB05
|
|||
| SuperDrug CAS ID |
cas=000086215
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H1 receptor (H1R) | Target Info | Antagonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
| Reactome | Histamine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7267). | |||
| REF 2 | Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. | |||
| REF 3 | Role of central histaminergic system in lorazepam withdrawal syndrome in rats. Pharmacol Biochem Behav. 2001 Apr;68(4):777-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.